FP
GENB

Flagship Pioneering’s Generate Biomedicines GENB Stock Holding History

Flagship Pioneering’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$783M Buy
+62,673,117
New +$765M 67.44% 1

Other funds holding GENB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
NC
Nvidia Corp Santa Clara, California $18.4B AUM 362.26% 1-Year Est. Return

Flagship Pioneering's GENB Position: Q1 2026 in Review

Flagship Pioneering opened a new position in Generate Biomedicines (GENB) in Q1 2026: 62,673,117 shares worth $783M. The stake represents 67.44% of the portfolio and ranks #1 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

  • Flagship Pioneering held 62,673,117 shares of Generate Biomedicines worth $783M as of Q1 2026.
  • Generate Biomedicines was a new Flagship Pioneering position in Q1 2026.
  • Generate Biomedicines made up 67.44% of Flagship Pioneering's portfolio in Q1 2026, its #1 holding.
  • 57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on Flagship Pioneering's 13F filing for Q1 2026, filed 15 May 2026.